|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9,400.00 JPY | +2.51% |
|
+2.17% | +14.04% |
| 02-06 | Japan's Nikkei rallies on earnings in unsteady trade before Sunday election | RE |
| 02-06 | Japanese drugmakers slump after Trump unveils discount drug website | RE |
Company Valuation: Chugai Pharmaceutical Co., Ltd.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 9,045,924 | 6,141,311 | 5,540,406 | 8,789,053 | 11,516,953 | 15,091,192 | 15,091,192 | - |
| Change | - | -32.11% | -9.78% | 58.64% | 31.04% | 31.03% | 0% | - |
| Enterprise Value (EV) 1 | 8,667,304 | 5,669,311 | 5,051,408 | 8,050,071 | 10,520,608 | 13,138,942 | 14,060,238 | 13,797,467 |
| Change | - | -34.59% | -10.9% | 59.36% | 30.69% | 24.89% | -0.95% | -1.87% |
| P/E ratio | 42.1x | 20.3x | 14.8x | 27x | 29.7x | 31.3x | 31.2x | 27.2x |
| PBR | 9.23x | 5.17x | 3.89x | 5.41x | 6.06x | 6.7x | 6.81x | 5.97x |
| PEG | - | 0.5x | 0.6x | -2.1x | 1.6x | 2.6x | 2.4x | 1.9x |
| Capitalization / Revenue | 11.5x | 6.14x | 4.4x | 7.91x | 9.84x | 10.8x | 11.2x | 10.3x |
| EV / Revenue | 11x | 5.67x | 4.01x | 7.24x | 8.99x | 10.4x | 10.5x | 9.45x |
| EV / EBITDA | 26.1x | 12.3x | 8.93x | 17.1x | 18.3x | 20.4x | 20.4x | 17.7x |
| EV / EBIT | 28.8x | 13.4x | 9.47x | 18.3x | 19.4x | 21.9x | 21.2x | 18.2x |
| EV / FCF | 81.2x | 35.3x | 27.7x | 21.6x | 47.8x | 71x | 31.1x | 27.3x |
| FCF Yield | 1.23% | 2.83% | 3.61% | 4.63% | 2.09% | 1.41% | 3.21% | 3.66% |
| Dividend per Share 2 | 55 | 76 | 78 | 80 | 98 | 272 | 140.4 | 150.2 |
| Rate of return | 1% | 2.03% | 2.32% | 1.5% | 1.4% | 3.3% | 1.53% | 1.64% |
| EPS 2 | 130.7 | 184.3 | 227.6 | 197.8 | 235.4 | 263.7 | 294.1 | 336.8 |
| Distribution rate | 42.1% | 41.2% | 34.3% | 40.4% | 41.6% | 103% | 47.8% | 44.6% |
| Net sales 1 | 786,900 | 999,800 | 1,259,946 | 1,111,367 | 1,170,611 | 1,257,900 | 1,342,132 | 1,459,763 |
| EBITDA 1 | 332,600 | 459,100 | 565,376 | 470,914 | 573,667 | 643,900 | 690,421 | 780,108 |
| EBIT 1 | 301,200 | 421,900 | 533,309 | 439,174 | 542,002 | 598,800 | 661,717 | 756,180 |
| Net income 1 | 214,700 | 303,000 | 374,429 | 325,472 | 387,317 | 434,000 | 483,991 | 554,210 |
| Net Debt 1 | -378,620 | -472,000 | -488,998 | -738,982 | -996,345 | -426,602 | -1,030,954 | -1,293,725 |
| Reference price 2 | 5,503.00 | 3,735.00 | 3,368.00 | 5,342.00 | 6,999.00 | 9,170.00 | 9,170.00 | 9,170.00 |
| Nbr of stocks (in thousands) | 1,643,817 | 1,644,260 | 1,645,014 | 1,645,274 | 1,645,514 | 1,645,713 | 1,645,713 | - |
| Announcement Date | 04/02/21 | 03/02/22 | 02/02/23 | 01/02/24 | 30/01/25 | 29/01/26 | - | - |
1JPY in Million2JPY
Estimates
P/E ratio, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
| 35.26x | 11.38x | 22.37x | 2.76% | 98.24B | ||
| 31.01x | 11.75x | 23.61x | 0.64% | 926B | ||
| 24.77x | 6.01x | 16.36x | 2.18% | 586B | ||
| 65.02x | 7.68x | 19.02x | 2.81% | 412B | ||
| 19.35x | 4.81x | 11.94x | 2.72% | 382B | ||
| 33.11x | 5.93x | 17.67x | 1.55% | 326B | ||
| 21.99x | 6.1x | 15x | 2.65% | 317B | ||
| 15.7x | 5.03x | 10.98x | 2.66% | 302B | ||
| 14.77x | 5.12x | 10.74x | 3.51% | 218B | ||
| 25.23x | 6.36x | 11.23x | 2.69% | 201B | ||
| Average | 28.62x | 7.02x | 15.89x | 2.42% | 376.74B | |
| Weighted average by Cap. | 29.63x | 7.51x | 17.11x | 2.07% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Equities
- 4519 Stock
- Valuation Chugai Pharmaceutical Co., Ltd.
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition
















